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Abstract
Background: HIV-associated anemia is common and associated with poor prognosis. However, its response to
antiretroviral treatment (ART) in rural Africa is poorly understood.
Methods: HIV-infected adults (≥15 years) who enrolled in HIV care at Haydom Lutheran Hospital in northern
Tanzania were included in the study. The effect of ART (zidovudine/stavudine + lamivudine + efavirenz/nevirapine)
on HIV-associated anemia was studied in a subset of patients who were anemic at the time they started ART and
had a follow-up hemoglobin measurement 12 months later. Pregnant women were excluded from the study, as
were women who had given birth within the past 6 weeks. Anemia was defined as hemoglobin <12 g/dL in
women and <13 g/dL in men. We applied paired sample T-tests to compare hemoglobin levels before and one
year after ART initiation, and logistic regression models to identify predictors of persistent anemia.
Results: At enrollment, mean hemoglobin was 10.3 g/dL, and 649 of 838 patients (77.4%) were anemic. Of the
anemic patients, 254 (39.1%) had microcytosis and hypochromia. Among 102 patients who were anemic at ART
initiation and had a follow-up hemoglobin measurement after 12 months, the mean hemoglobin increased by 2.5
g/dL (P < 0.001); however, 39 patients (38.2%) were still anemic after 12 months of ART. Independent predictors of
persistent anemia were mean cell volume in the lower quartile (<76.0 fL; Odds Ratio [OR] 4.34; 95% confidence
interval [CI] 1.22-15.5) and a zidovudine-containing initial regimen (OR 2.91; 95% CI 1.03-8.19).
Conclusions: Most patients had anemia at enrollment, of whom nearly 40% had microcytosis and hypochromia
suggestive of iron deficiency. The mean hemoglobin increased significantly in patients who received ART, but one
third were still anemic 12 months after ART initiation indicating that additional interventions to treat HIV-associated
anemia in rural Africa might be warranted, particularly in patients with microcytosis and those treated with
zidovudine.
Background
Anemia is a common feature of HIV infection, occur-
ring in approximately 35% of patients who initiate anti-
retroviral treatment (ART) in Europe and North
America [1]. In addition to causing reduced physical
functioning and quality of life, a number of studies have
found that anemia at the time of ART initiation is asso-
ciated with HIV disease progression and mortality [2-9].
Indeed, in the EuroSIDA cohort, patients with severe
anemia at baseline had 13 times greater risk of death
during the first year of ART than patients with normal
hemoglobin levels [3]. Similar findings have recently
been reported from Tanzania, Côte d’Ivoire, South
Africa and Malawi [2,6,8].
It is uncertain whether the association between anemia
and mortality is causal or whether anemia acts as a surro-
gate marker of underlying disease. Previous studies have
found that the incidence of anemia increases with pro-
gression of HIV infection [9-11], and anemia is a known
feature of certain opportunistic infections such as tuber-
culosis (TB), atypical mycobacteria and parvovirus B19
[12]. Several other etiologic factors may also be involved
in the development of HIV-associated anemia, including
micronutrient deficiencies, immunological myelosuppres-
sion, impaired erythropoietin production and blood loss
from intestinal opportunistic disease.
Management of HIV-associated anemia in high-
income countries includes erythropoietin treatment,
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and improved survival, but high costs restrict its use in
resource-limited settings [13]. Furthermore, studies from
Europe and North America have shown that ART itself
can be an effective treatment of the anemia of HIV
infection [3,14-16]. However, it remains to be seen if the
same holds true in rural Africa, where co-morbidities
such as micronutrient deficiencies, malaria, TB, parasitic
infections and genetic hematological disorders are com-
mon. Therefore, we aimed to characterize the anemia
and cell indices in a cohort of HIV-infected adults in
rural Tanzania, and to study the effect of ART and
other factors on the hemoglobin evolution over time.
Methods
Study setting and participants
Our study was carried out in Tanzania, a low-income
country in East Africa, with an estimated adult HIV pre-
valence of 5.7% [17]. Haydom Lutheran Hospital is a
400-bed hospital in Manyara region in northern Tanza-
nia. The hospital is the main health care provider to a
rural population of about 260,000 people, in an area
where the majority rely on subsistence farming and
pastoralism.
The HIV Care and Treatment Centre in Haydom has
provided ART free of charge since October 2003. Clini-
cal officers, under supervision of a physician, have been
responsible for medical follow-up of patients. Most of
the patients who enroll in the HIV program are diag-
nosed either through voluntary testing and counselling
in the villages or testing of hospitalized patients with
clinical suspicion of HIV/AIDS. Hence, many patients
have advanced immunodeficiency at the time of
enrollment.
In the present study we describe the baseline hemato-
logical profile in a cohort of treatment-naïve individuals
aged 15 years or older who enrolled in HIV care at Hay-
dom Lutheran Hospital between October 2003 and Jan-
uary 2008. In a subset of patients who were anemic at
t h et i m et h e ys t a r t e dA R Ta n dh a daf o l l o w - u ph e m o -
globin measurement 12 months later we studied the
effect of ART on HIV-associated anemia. Women who
were pregnant at baseline or became pregnant during
the observation period were excluded from the study, as
were women who had given birth within the past 6
weeks, since the physiological hemodilution in preg-
nancy and subsequent blood loss during delivery would
have precluded the results. Ethical approval was
obtained from the Medical Research Coordinating Com-
mittee of the National Institute for Medical Research in
Tanzania and Regional Committee for Medical Research
Ethics in Norway. Patients gave written consent to parti-
cipate in the study.
Treatment, monitoring and laboratory investigations
ART was initiated in accordance with guidelines from
the World Health Organization (WHO) and the
National AIDS Control Program [18-21]: WHO stage 4
irrespective of CD4 cell count, WHO stage 3 with CD4
≤350 cells/μL, or CD4 ≤200 cells/μLw i t ha n yW H O
stage. However, reliable CD4 cell counts were not avail-
able until September 2006, so most patients started
ART based on clinical criteria only (WHO stage 3 or 4).
First-line treatment comprised stavudine or zidovu-
dine, combined with lamivudine, and either nevirapine
or efavirenz. Regimen choice was subject to availability,
with use of a generic fixed-dose combination of stavu-
dine, lamivudine and nevirapine whenever possible. Efa-
virenz was used in patients with concomitant TB
treatment. None of the patients switched to second-line
ART during the observation period. Patients with CD4
≤200 cells/μL or WHO stage 3 or 4 disease got co-tri-
moxazole prophylaxis 960 mg thrice weekly or 480 mg
daily. Patients were seen by a clinical officer every 3
months, and CD4 cell count and full blood count
(including hemoglobin) was scheduled every 3-6 months
as part of routine care.
HIV infection was established using two different
rapid antibody tests, Determine HIV-1/2 (Abbott
laboratories, Abbott Park, IL, USA) and Capillus HIV-1/
2 (Trinity Biotech, Bray, Co Wicklow, Ireland), in accor-
dance with recommendations from the National AIDS
Control Program [21]. Standard hematology was mea-
sured using Sysmex KX-21 Hematology Analyzer (Sys-
mex Corp., Kobe, Japan). Body mass index (BMI, weight
in kilograms divided by height in meters squared) was
used to assess nutritional status. Body weight was mea-
sured at each clinic visit using the same manual scale,
and height was measured using a stadiometer mounted
on the scale.
Anemia was defined as a hemoglobin level <12 g/dL
for women and <13 g/dL for men, in accordance with
WHO guidelines [22]. We classified the anemia as mild
(10-12 g/dL for women and 10-13 g/dL for men), mod-
erate (8-10 g/dL) and severe (<8 g/dL). Microcytosis was
defined as a mean cell volume (MCV) <80 fL and hypo-
chromia as a mean corpuscular hemoglobin (MCH) <26
pg [23]. In patients who died, anemia was considered a
contributing factor if the last hemoglobin before death
was <6.5 g/dL [24], or if anemia was recorded as a
death cause by the clinician in charge.
Statistical analysis
In general, we applied the first available laboratory result
as the enrollment value. If two values were obtained
within a month, the mean was employed. In the study
on the effect of ART on HIV-associated anemia, only
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and had a follow-up hemoglobin measurement 12
months later were considered. The laboratory result
obtained closest to the start of ART was used as base-
line, and this value had to be no more than 3 months
prior to ART initiation. Laboratory results obtained dur-
ing the first year on ART were rounded off to the near-
est 3 months.
To avoid loss of power we attempted to avoid dichot-
omization of continuous variables, such as BMI, MCV
and MCH [25]. Instead, BMI was categorized according
to recognized cutpoints [26], whereas for MCV and
MCH we used quartiles. Chi-square tests were used to
study factors associated with anemia at enrollment.
Paired samples T-tests were used to compare hemoglo-
bin levels before and 12 months after ART initiation.
Multivariable logistic regression analysis was used to
identify predictors of persistent anemia after 12 months
of ART. Clinical and laboratory variables were initially
examined in bivariable models adjusting for baseline
hemoglobin. CD4 cell counts were excluded because of
too few observations. All variables with P < 0.2 in bivari-
able analyses were then entered in a multivariable
model, using the forward stepwise (Wald) method. Mul-
ticollinearity was excluded using Spearman’s correlation
coefficient with a cutoff at 0.7. Data were analysed with
SPSS version 16.0 for Windows (SPSS Inc., Chicago, Illi-
nois, USA). All tests were two-sided and level of signifi-
cance was set at P < 0.05.
Results
Patient characteristics at enrollment
A total of 838 HIV-infected adults who enrolled in the
HIV program between October 3, 2003, and January 31,
2008, were included in this study (Figure 1). The mean
age was 37 years (standard deviation [SD] 10) and 545
patients (65.0%) were women. Mean BMI was 18.6 kg/
m
2 (SD 3.4). At enrollment, 399 patients (47.6%) had
clinical AIDS (WHO stage 4), 245 (29.2%) had WHO
stage 3, 97 (11.6%) had WHO stage 2, and 97 (11.6%)
had WHO stage 1 disease. Ninety-eight patients (11.7%)
were on TB treatment when they enrolled in care.
The mean hemoglobin at enrollment was 10.3 g/dL
(SD 2.4), the mean MCV was 82.5 fL (SD 7.8), and the
mean MCH was 26.6 pg (SD 3.2). Overall, 649 of 838
patients (77.4%) met the definition of anemia: 269
patients (32.1%) had mild anemia, 238 (28.4%) had mod-
erate anemia, and 142 (16.9%) had severe anemia. Out
of 649 anemic patients, 254 (39.1%) had microcytosis
and hypochromia, suggestive of iron deficiency, whereas
52 (8.0%) had hypochromia with normocytosis, and 18
(2.8%) had microcytosis with normochromia.
Table 1 gives an overview of patient characteristics at
enrollment and associations with anemia. Female
gender, clinical AIDS, TB, low BMI, microcytosis and
hypochromia were all significantly associated with ane-
mia at enrollment.
Hemoglobin evolution during antiretroviral treatment
Out of 838 adults included in the study, 102 patients
who were anemic at ART initiation and had a follow-up
hemoglobin measurement 12 months later were selected
for the sub-study on ART and anemia. Reasons for not
being included in this sub-study are given in figure 1.
Among 102 patients in this sub-study, the mean age
was 36 years (SD 10) and 75 patients (73.5%) were
women. Mean BMI was 18.2 kg/m
2 (SD 3.3). Sixty-one
patients (59.8%) had clinical AIDS at ART initiation.
Fourteen patients (13.7%) were on TB treatment when
they initiated ART and 8 more started TB treatment
during the observation period of 12 months. Initial ART
regimen was stavudine/lamivudine/nevirapine in 62
patients (60.8%), stavudine/lamivudine/efavirenz in 17
(16.7%), zidovudine/lamivudine/nevirapine in 16 (15.7%),
and zidovudine/lamivudine/efavirenz in 7 (6.9%). Only
17 patients had a baseline CD4 measurement; the mean
CD4 cell count was 140 cells/μL (SD 149).
838 HIV-infected adults 
with a baseline 
hematology result 
649 with anemia
102 non-pregnant 
adults with anemia at 
ART initiation and a 
follow-up hemoglobin 
result after 12 months
189 with normal 
hemoglobin
245 not started ART
98 died
32 lost to follow-up
31 transferred out
39 pregnant or puerperal
37 on ART <12 months
65 without a hemoglobin 
result after 12 months
Figure 1 Profile of the study cohort, Haydom Lutheran
Hospital, Tanzania.
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was 9.9 g/dL (SD 1.5). Eleven patients (10.8%) had
severe anemia, 37 (36.3%) had moderate anemia and 54
(52.9%) had mild anemia. Patients with severe anemia
were less likely to start a zidovudine-containing initial
regimen (1 of 11; 9.1%) than patients with moderate (8
of 37; 21.6%) or mild anemia (14 of 54; 25.9%), but the
difference was not statistically significant (P = 0.470).
After receiving ART for 12 months the mean hemoglo-
bin increased to 12.4 g/dL (SD 1.9) (P <0 . 0 0 1 )( F i g u r e
2); however, 39 patients (38.2%) were still anemic, of
whom 2 (2.0%) had severe anemia, 7 (6.9%) had moder-
ate anemia and 30 (29.4%) had mild anemia. The two
patients with severe anemia at 12 months both had a
falling hemoglobin level during ART. The greatest
hemoglobin change (+4.6 g/dL) was seen in patients
with severe anemia at the time of ART initiation, com-
pared to +3.0 g/dL in patients with moderate anemia
and +1.8 g/dL in patients with mild anemia.
To assess whether the hemoglobin increase could be a
result of other factors associated with enrollment in
HIV care rather than ART itself, we studied the hemo-
globin evolution in 18 non-pregnant adults who were
anemic at enrollment and had a follow-up hemoglobin
measurement 12 months later, but did not start ART. In
this group there was no statistically significant hemoglo-
bin increase: the mean hemoglobin was 10.1 g/dL (SD
1.5) at enrollment and 10.9 g/dL (SD 2.1) after 12
Table 1 Patient characteristics and degree of anemia at enrollment
Variables Normal
n (%)
Mild anemia
a
n (%)
Moderate anemia
b
n (%)
Severe anemia
c
n (%)
P
All (n = 838) 189 (22.6) 269 (32.1) 238 (28.4) 142 (16.9)
Gender 0.046
Female 115 (21.1) 165 (30.3) 171 (31.4) 94 (17.2)
Male 74 (25.2) 104 (35.5) 67 (22.9) 48 (16.4)
Age (years) 0.726
<30 40 (20.1) 61 (30.7) 61 (30.7) 37 (18.6)
30-39 75 (22.1) 106 (31.3) 98 (28.9) 60 (17.7)
≥40 74 (24.7) 102 (34.0) 79 (26.3) 45 (15.0)
AIDS
d <0.001
Yes 48 (12.0) 109 (27.3) 146 (36.6) 96 (24.1)
No 141 (32.1) 160 (36.4) 92 (21.0) 46 (10.5)
Tuberculosis
e 0.001
Yes 9 (9.2) 34 (34.7) 28 (28.6) 27 (27.5)
No 180 (24.3) 235 (31.8) 210 (28.4) 115 (15.5)
BMI (kg/m2)
f <0.001
<16 17 (8.8) 49 (25.4) 67 (34.7) 60 (31.1)
16-18.4 46 (19.7) 74 (31.8) 76 (32.6) 37 (15.9)
≥18.5 118 (33.5) 134 (38.1) 76 (21.6) 24 (6.8)
MCV (fL) <0.001
<80 36 (11.7) 90 (29.2) 116 (37.7) 66 (21.4)
≥80 153 (28.9) 179 (33.8) 122 (23.0) 76 (14.3)
MCH (pg) <0.001
<26 35 (10.3) 95 (27.9) 130 (38.1) 81 (23.7)
≥26 154 (31.0) 174 (35.0) 108 (21.7) 61 (12.3)
aHemoglobin 10-12 g/dL (10-13 g/dL for men).
bHemoglobin 8-10 g/dL.
cHemoglobin <8 g/dL.
dWorld Health Organization clinical stage 4.
eOn tuberculosis
treatment at enrollment.
f60 values missing (n = 778).
BMI, body mass index; MCV, mean cell volume; MCH, mean corpuscular hemoglobin.
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Figure 2 Mean hemoglobin at baseline and after receiving
antiretroviral treatment for 3, 6, 9 and 12 months. Only patients
with anemia at baseline and a follow-up hemoglobin after 12
months are presented (n = 102). Vertical bars indicate standard
errors of the mean.
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patients who did not start ART had a 6-fold increased
risk of persistent anemia after 12 months compared to
those who started ART (Odds Ratio [OR] 5.99; 95%
confidence interval [CI] 1.82-19.8; P = 0.003).
Sixty-five patients who were alive and in care 12
months after ART initiation, but who did not have a fol-
low-up hemoglobin measurement, were excluded from
our analysis. These patients had a similar age (mean 38
years) and sex (67.7% female) distribution as in the
main analysis. Forty-one of these patients had a hemo-
globin measurement at 9 months, and they showed a
similar improvement as patients in the main analysis,
from a mean hemoglobin of 9.6 g/dL (SD 1.8) at base-
line to 12.3 g/dL (SD 1.6) at 9 months (P < 0.001).
Ninety-eight patients who died during the first year on
ART were also excluded from our analysis, 68 of whom
died within the first three months. At the time of ART
initiation the mean hemoglobin among patients who
died was 8.8 g/dL (SD 1.7), significantly lower than
among patients in the main analysis (P < 0.001). We
reviewed the records of these patients and found that
a n e m i ac o n t r i b u t e dt ot h ed e a t hi n1 5o f9 8p a t i e n t s .
Thirteen of 15 anemia-related deaths occurred in
patients who received a stavudine-containing regimen,
of whom 8 had severe anemia already at the time of
ART initiation. Two patients died of presumed hemato-
toxic effects of zidovudine, 58 and 94 days after ART
initiation, respectively.
Predictors of persistent anemia
Among patients who were anemic at ART initiation,
only MCV in the lower quartile (<76.0 fL) significantly
predicted persistent anemia 12 months later in bivari-
able logistic regression analysis adjusted for baseline
hemoglobin, whereas MCH in the lower quartile (<23.8
pg) and a zidovudine-containing initial regimen were
borderline significant (Table 2). MCV and MCH were
collinear (Spearman’s correlation coefficient 0.86);
hence, only MCV was included in the multivariable
model. In the final multivariable analysis, MCV in the
lower quartile (OR 4.34; 95% CI 1.22-15.5; P = 0.023)
and a zidovudine-containing initial regimen (OR 2.91;
95% CI 1.03-8.19; P = 0.043) were significantly asso-
ciated with persistent anemia.
During the first year on ART, 3 patients switched
from stavudine to zidovudine and 4 from zidovudine to
stavudine, 2 of whom switched because of severe ane-
mia. To assess whether drug substitutions might have
confounded our results, we conducted a sensitivity ana-
lysis where these patients were excluded. In the result-
ing multivariable model, both MCV in the lower
quartile (OR 4.30; 95% CI 1.16-15.9; P =0 . 0 2 9 )a n da
zidovudine-containing initial regimen (OR 3.32; 95% CI
1.10-10.0; P = 0.034) remained strong and significant
predictors of persistent anemia.
Discussion
In this study 77.4% of HIV-infected adults had anemia
at the time they enrolled in HIV care. Women were
more likely than men to be anemic, reflecting the overall
higher prevalence of anemia in women due to menstrual
blood loss and multiple deliveries. Furthermore, anemia
at enrollment was associated with advanced immunode-
ficiency (WHO stage 4 and low BMI) and TB, in line
with previous studies [9-11,27,28]. The overall preva-
lence of anemia was much higher in our study than in
studies from high-income countries, but comparable to
results from certain other African countries such as
Nigeria, Côte d’Ivoire, Malawi and South Africa
[2,29,30], probably because of more advanced immuno-
deficiency at enrollment as well as higher prevalence of
anemia in the general population in sub-Saharan Africa
[22]. Interestingly, in a recent study from our study site
the mean hemoglobin among HIV-negative healthy
adults (58.8% females, mean age 32.6 years) was 13.2 g/
dL, compared to 10.3 g/dL among HIV-positive adults
in our study [31]. In other words, anemia is far more
frequent in HIV-infected adults in this region than in
their HIV-negative counterparts.
The hemoglobin level increased significantly in
patients who received ART; on average the hemoglobin
increased 2.5 g/dL over the first 12 months among
patients who were anemic at ART initiation. Previous
studies have reported that ART is associated with reso-
lution of HIV-associated anemia in Europe and North
America [3,14,15]. More recently, similar findings have
been reported from sub-Saharan Africa. In a study from
Abidjan, Côte d’Ivoire, the prevalence of anemia (hemo-
globin <10.5 g/dL) decreased from 31% at baseline to
17% after 6 months on a zidovudine-containing ART
regimen [32]. A study from rural Uganda found that the
mean hemoglobin increased from 11.3 g/dL at baseline
to 12.8 g/dL after 12 months on ART [33]. Finally, a
recent study from Kampala, Uganda, reported that the
median hemoglobin increased by 2.9 g/dL during the
first 6 months of ART among patients who were anemic
(hemoglobin <9.5 g/dL) at ART initiation [34]. Although
the magnitude of the hemoglobin increase might vary
depending on the baseline hemoglobin level and degree
of immunodeficiency, our study confirms that HIV-asso-
ciated anemia in rural Tanzania, as in industrialized
countries, can be reversed by ART in the majority of
subjects. This suggests that HIV-associated anemia in
this setting is caused mainly by factors related to the
HIV infection itself, such as chronic inflammation and
opportunistic infections, rather than tropical diseases or
specific environmental factors.
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hemoglobin level. A low MCV was a strong and inde-
pendent predictor of persistent anemia in our study.
Microcytosis was also associated with persistent anemia
in the Women’s Interagency HIV Study in USA [15],
and with an increased risk of developing severe anemia
in a recent study from Uganda [34]. Classically, the
most common cause of microcytosis is iron deficiency
[35], which would explain why these patients were less
likely to recover from anemia. On the other hand, iron
supplementation in HIV is controversial, as there is evi-
dence of iron accumulation and enhanced oxidative
stress with progression of HIV infection [36]. Interest-
ingly, in a study from Malawi only 16% of patients with
severe HIV-associated anemia (hemoglobin <7 g/dL)
had iron deficiency, whereas 19% had iron excess,
assessed by bone marrow examination [37]. Moreover, a
large study from Gambia found that elevated iron status
strongly predicted mortality in HIV-infected adults [38].
In sub-Saharan Africa iron supplementation is com-
monly prescribed or self-supplemented; hence, there is a
need for further studies to clarify its role in patients
with HIV-associated anemia.
An initial zidovudine-containing ART regimen was
also associated with persistent anemia in our study,
increasing the risk by nearly 3 times compared to regi-
mens containing stavudine. The potential myelosuppres-
sive effect of zidovudine has been known for more than
two decades [39], but its significance in clinical practice
is still debated. For instance, a recent study from
Table 2 Predictors of persistent anemia after 12 months of ART among 102 HIV-infected adults who were anemic at
ART initiation
Crude
a Adjusted
b
Variables Total Anemic after 12 months (%) OR (95% CI) P OR (95% CI) P
Gender
Female 75 30 (40.0) 1
Male 27 9 (33.3) 0.85 (0.33-2.20) 0.744
Age (years)
<30 26 10 (38.5) 1
30-39 42 19 (45.2) 1.45 (0.52-4.01) 0.476
≥40 34 10 (29.4) 0.77 (0.25-2.33) 0.641
AIDS
c
No 41 16 (39.0) 1
Yes 61 23 (37.7) 0.93 (0.41-2.13) 0.862
Tuberculosis
d
No 80 31 (38.8) 1
Yes 22 8 (36.4) 0.69 (0.24-1.94) 0.477
BMI (kg/m
2)
<16 26 9 (34.6) 1
16-18.4 35 15 (42.9) 1.62 (0.55-4.78) 0.382
≥18.5 40 14 (35.0) 1.24 (0.42-3.64) 0.702
MCV (fL)
≥87.5 25 6 (24.0) 1 1
82.1-87.4 27 9 (33.3) 1.47 (0.43-5.06) 0.538 1.35 (0.38-4.72) 0.644
76.0-82.0 25 9 (36.0) 1.75 (0.51-6.00) 0.377 1.42 (0.39-5.13) 0.595
<76.0 25 15 (60.0) 4.05 (1.17-14.1) 0.028 4.34 (1.22-15.5) 0.023
MCH (pg)
≥28.1 26 7 (26.9) 1
26.6-28.0 24 7 (29.2) 1.14 (0.33-3.95) 0.841
23.8-26.5 26 10 (38.5) 1.70 (0.52-5.52) 0.380
<23.8 26 15 (57.7) 3.20 (0.97-10.5) 0.056
Initial regimen
Stavudine 79 27 (34.2) 1 1
Zidovudine 23 12 (52.2) 2.46 (0.93-6.54) 0.071 2.91 (1.03-8.19) 0.043
aAdjusted for baseline hemoglobin.
bAdjusted for baseline hemoglobin and the other variables listed in the final model. MCH was excluded because of
collinearity with MCV.
cWorld Health Organization clinical stage 4.
dOn tuberculosis treatment at ART initiation or started within the observation period of
12 months.
OR, odds ratio; CI, confidence interval; BMI, body mass index; MCV, mean cell volume; MCH, mean corpuscular hemoglobin.
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anemia (hemoglobin ≤8g / d Lw i t h i n6m o n t h so fA R T
initiation) in patients on zidovudine, and concluded that
zidovudine - in the absence of better alternatives -
should not be withheld even in patient with a hemoglo-
bin below 8 g/dL at the time of ART initiation. How-
ever, the same study reported that anemic patients
(hemoglobin ≤9.5 g/dL) who started a stavudine-con-
taining regimen had a significantly larger hemoglobin
increase than those who started zidovudine (3.1 g/dL vs.
2.5 g/dL) [34]. This is in line with a meta-analysis of 6
randomized trials, in which the mean hemoglobin level
was 0.8 g/dL lower in patients who received zidovudine
than those who received stavudine after 48 weeks on
ART [40]. These differences are small, but the Euro-
SIDA study indicated that even subtle differences in
hemoglobin level might be of clinical significance;
indeed, a 1 g/dL decrease in the latest hemoglobin level
increased the hazard of death by 57%, after adjusting for
demographic factors, ART regimen, AIDS status, CD4
cell count and viral load [3]. The 2010 revision of the
WHO guidelines for resource-limited settings recom-
mend to start ART with a regimen consisting of zidovu-
dine or tenofovir in combination with lamivudine and a
non-nucleoside reverse transcriptase inhibitor, in order
to avoid the long-term toxicities of stavudine [24]. Our
study underscores the possible caveats of zidovudine,
and suggests that other drugs might be preferable in
anemic patients, especially in countries where anemia is
endemic.
Before the HIV era, recommendations for manage-
ment of anemia in classical tropical medicine included
screening for malaria, treatment for helminthic infec-
tions and iron/folic acid supplementation [41]. In the
setting of a generalized HIV epidemic, which is the case
in most of sub-Saharan Africa, however, these guidelines
are overdue for revision, since HIV-associated anemia
requires a different approach. Indeed, in a study of
patients admitted at a large urban hospital in Malawi
with severe anemia (hemoglobin <7 g/dL), 79% had HIV
and 37% had TB, and relatively few had classical causes
of anemia such as heavy hookworm infections (9%),
malaria (14%) or iron deficiency (25%) [37]. Manage-
ment of anemia in settings with a high prevalence of
HIV should always include an HIV test, and ART
should be initiated if no other explanation of the anemia
can be identified. Our study suggests that this would be
sufficient to correct the anemia in the majority of sub-
jects, and that MCV can be a useful additional test to
identify patients in whom additional treatment (such as
iron supplementation) might be required.
T h e r ew e r es o m el i m i t a t i o n so fo u rs t u d y .M o s t
importantly there may have been a selection bias
towards patients with a more favorable prognosis in the
sub-study on the effect of ART on anemia, since we
only included patients with a follow-up hemoglobin
measurement after 12 months. Patients who died during
the first year on ART might have had a different hemo-
globin evolution, but since the majority of deaths
occurred within the first 3 months, few of these had a
second laboratory measurement. We also excluded
patients who were still receiving ART, but did not have
a hemoglobin measurement after 12 months. If these
patients were less likely to be anemic than the others,
our results could be biased (selection by indication);
however, patients who were excluded had a similar
hemoglobin increase at 9 months as the patients in our
main analysis. Furthermore, our study was limited by
lack of adherence data, and it is possible that poor
adherence contributed to persistent anemia in some
patients. On the other hand, in a previous study from
the same cohort, we found that 94.8% of patients had
suppressed viraemia after 1 year of ART, indicating
good adherence in the majority of subjects [42]. Finally,
given the observational nature of the study, the lack of
randomization made comparison between different ART
regimens susceptible to bias. For instance, patients with
severe anemia at baseline were less likely to receive a
zidovudine-containing regimen; however, we adjusted
for baseline hemoglobin in the logistic regression mod-
els. Nevertheless, our results may have been influenced
by other confounding factors and bias not accounted for
in the analysis.
Conclusions
In conclusion, we found that the majority of patients
who enrolled in HIV care at a rural hospital in Tanza-
nia were anemic, and that nearly 40% of the anemic
patients had microcytosis and hypochromia suggestive
of iron deficiency. Patients who were anemic at the
time of ART initiation had a strong and significant
hemoglobin increase over the initial 12 months of
ART. However, more than one third of patients did
not reach normal hemoglobin levels while on ART,
and a low MCV and a zidovudine-containing initial
regimen were independent predictors of persistent ane-
mia. Our study indicate that although ART effectively
reverses HIV-associated anemia in the majority of indi-
viduals, additional interventions might be warranted in
a subset of patients.
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